{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:01:36Z","timestamp":1793152896441,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.urology.2025.04.056","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T20:30:25Z","timestamp":1746736225000},"page":"152-158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["GLP-1 Agonist Use Among Men With Localized Prostate Cancer: A Narrative Review and Rationale for Prospective Clinical Trials"],"prefix":"10.1016","volume":"201","author":[{"given":"Andrew","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Frigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zayd","family":"Razouki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstratios","family":"Koutroumpakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Lawen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Hamilton-Reeves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"DiGiovanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel","family":"Higgason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebekka S.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian F.","family":"Chapin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis","family":"Pettaway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisly","family":"Chery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Troncoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Logothetis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie R.","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3852-8199","authenticated-orcid":false,"given":"Justin R.","family":"Gregg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2025.04.056_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urology.2025.04.056_bib2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1158\/1055-9965.EPI-14-0707","article-title":"Physical activity and survival among men diagnosed with prostate cancer","volume":"24","author":"Bonn","year":"2015","journal-title":"Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol"},{"key":"10.1016\/j.urology.2025.04.056_bib3","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/aje\/kws261","article-title":"Index-based dietary patterns and the risk of prostate cancer in the NIH-AARP diet and health study","volume":"177","author":"Bosire","year":"2013","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.urology.2025.04.056_bib4","first-page":"137","article-title":"Obesity and prostate cancer. Recent results cancer res. Fortschritte Krebsforsch","volume":"208","author":"Cao","year":"2016","journal-title":"Progres Dans Rech Sur Cancer"},{"key":"10.1016\/j.urology.2025.04.056_bib5","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1200\/JCO.2010.31.5226","article-title":"Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study","volume":"29","author":"Kenfield","year":"2011","journal-title":"J Clin"},{"key":"10.1016\/j.urology.2025.04.056_bib6","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/bco2.110","article-title":"Increased body mass index is associated with operative difficulty during robot-assisted radical prostatectomy","volume":"3","author":"Shapiro","year":"2022","journal-title":"BJUI Compass"},{"key":"10.1016\/j.urology.2025.04.056_bib7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.urology.2023.02.013","article-title":"Association between presurgical weight status and urinary and sexual function in prostate cancer patients treated by radical prostatectomy: a prospective cohort study","volume":"175","author":"Yang","year":"2023","journal-title":"Urology"},{"key":"10.1016\/j.urology.2025.04.056_bib8","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s00345-022-03989-2","article-title":"Impact of obesity on perioperative, functional and oncological outcomes after robotic-assisted radical prostatectomy in a high-volume center","volume":"40","author":"Sarychev","year":"2022","journal-title":"World J Urol"},{"key":"10.1016\/j.urology.2025.04.056_bib9","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1093\/jnci\/djp122","article-title":"Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis","volume":"101","author":"Cooperberg","year":"2009","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.urology.2025.04.056_bib10","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer","volume":"375","author":"Hamdy","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2025.04.056_bib11","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.juro.2010.10.061","article-title":"Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe Sweden","volume":"185","author":"Berglund","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2025.04.056_bib12","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1001\/jama.2019.20207","article-title":"Effect of a behavioral intervention to increase vegetable consumption on cancer progression among men with early-stage prostate cancer: the MEAL randomized clinical trial","volume":"323","author":"Parsons","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.urology.2025.04.056_bib13","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1001\/jamaoncol.2021.3067","article-title":"Effects of exercise on cardiorespiratory fitness and biochemical progression in men with localized prostate cancer under active surveillance: the ERASE randomized clinical trial","volume":"7","author":"Kang","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urology.2025.04.056_bib14","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/cncr.33182","article-title":"Adherence to the Mediterranean diet and grade group progression in localized prostate cancer: an active surveillance cohort","volume":"127","author":"Gregg","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2025.04.056_bib15","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/01.ju.0000169487.49018.73","article-title":"Intensive lifestyle changes may affect the progression of prostate cancer","volume":"174","author":"Ornish","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2025.04.056_bib16","doi-asserted-by":"crossref","unstructured":"Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2021; 143. Accessed July 12, 2023. https:\/\/www.ahajournals.org\/doi\/10.1161\/CIR.0000000000000973.","DOI":"10.1161\/CIR.0000000000000973"},{"key":"10.1016\/j.urology.2025.04.056_bib17","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41568-020-0267-9","article-title":"Prostate carcinogenesis: inflammatory storms","volume":"20","author":"de Bono","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.urology.2025.04.056_bib18","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1158\/1055-9965.EPI-14-0458","article-title":"Serum lipid profile and risk of prostate cancer recurrence: results from the SEARCH database","volume":"23","author":"Allott","year":"2014","journal-title":"Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol"},{"key":"10.1016\/j.urology.2025.04.056_bib19","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.1038\/s41467-020-17645-z","article-title":"Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancer","volume":"11","author":"Vykoukal","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.urology.2025.04.056_bib20","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s40364-024-00678-7","article-title":"Validation of a prognostic blood-based sphingolipid panel for men with localized prostate cancer followed on active surveillance","volume":"12","author":"Gregg","year":"2024","journal-title":"Biomark Res"},{"key":"10.1016\/j.urology.2025.04.056_bib21","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2337\/dc17-1825","article-title":"Neoplasms reported with liraglutide or placebo in people with type 2 diabetes: results from the LEADER randomized trial","volume":"41","author":"Nauck","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.urology.2025.04.056_bib22","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/07435800.2021.1955255","article-title":"Differential risk of cancer associated with Glucagon-like Peptide-1 receptor agonists: analysis of real-world databases","volume":"47","author":"Wang","year":"2022","journal-title":"Endocr Res"},{"key":"10.1016\/j.urology.2025.04.056_bib23","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/EDE.0000000000001486","article-title":"Incretin-based drugs and the incidence of prostate cancer among patients with type 2 diabetes","volume":"33","author":"Lu","year":"2022","journal-title":"Epidemiol Camb Mass"},{"key":"10.1016\/j.urology.2025.04.056_bib24","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1007\/s00125-023-05972-x","article-title":"Potential preventive properties of GLP-1 receptor agonists against prostate cancer: a nationwide cohort study","volume":"66","author":"Skriver","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.urology.2025.04.056_bib25","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.2337\/db13-1169","article-title":"Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth","volume":"63","author":"Nomiyama","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.urology.2025.04.056_bib26","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1111\/jdi.13247","article-title":"Activation of overexpressed glucagon-like peptide-1 receptor attenuates prostate cancer growth by inhibiting cell cycle progression","volume":"11","author":"Shigeoka","year":"2020","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.urology.2025.04.056_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0139709","article-title":"Combined treatment with Exendin-4 and Metformin attenuates prostate cancer growth","volume":"10","author":"Tsutsumi","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.urology.2025.04.056_bib28","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2020.12.030","article-title":"Insulinemic and inflammatory dietary patterns and risk of prostate cancer","volume":"79","author":"Fu","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2025.04.056_bib29","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41391-017-0001-1","article-title":"Phase II prospective randomized trial of weight loss prior to radical prostatectomy","volume":"21","author":"Henning","year":"2018","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.urology.2025.04.056_bib30","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1158\/1078-0432.CCR-21-4272","article-title":"The impact of PIK3R1 mutations and Insulin-PI3K-Glycolytic pathway regulation in prostate cancer","volume":"28","author":"Chakraborty","year":"2022","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.urology.2025.04.056_bib31","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/nrc.2016.81","article-title":"Serine and one-carbon metabolism in cancer","volume":"16","author":"Yang","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.urology.2025.04.056_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.574667","article-title":"The role of the CXCL12\/CXCR4\/CXCR7 Chemokine Axis in cancer","volume":"11","author":"Shi","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.urology.2025.04.056_bib33","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/JU.0000000000001321","article-title":"The association of peri-prostatic fat and grade group progression in men with localized prostate cancer on active surveillance","volume":"205","author":"Gregg","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2025.04.056_bib34","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1158\/1940-6207.CAPR-11-0182","article-title":"Dietary energy balance modulates prostate cancer progression in Hi-Myc mice","volume":"4","author":"Blando","year":"2011","journal-title":"Cancer Prev Res (Phila Pa)"},{"key":"10.1016\/j.urology.2025.04.056_bib35","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1038\/s41388-022-02466-9","article-title":"CXCR4 and CXCR7 signaling promotes tumor progression and obesity-associated epithelial-mesenchymal transition in prostate cancer cells","volume":"41","author":"Ahn","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.urology.2025.04.056_bib36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.eururo.2023.04.015","article-title":"Challenging the prevailing therapeutic dogma for prostate cancer: the case for an overlap syndrome","volume":"85","author":"Logothetis","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2025.04.056_bib37","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1097\/JU.0000000000003849","article-title":"Impact of weight management on obesity-driven biomarkers of prostate cancer progression","volume":"211","author":"Bechtel","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2025.04.056_bib38","doi-asserted-by":"crossref","DOI":"10.1038\/s41391-024-00870-8","article-title":"Body composition as a determinant of the therapeutic index with androgen signaling inhibition","author":"Hahn","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.urology.2025.04.056_bib39","article-title":"Risk factors for cardiovascular-specific mortality in patients with prostate cancer: a surveillance, epidemiology, and end results (SEER)-based study","volume":"15","author":"Alhadeethi","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.urology.2025.04.056_bib40","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes","volume":"146","author":"Marx","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.urology.2025.04.056_bib41","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/aps.2018.40","article-title":"Leptin, cardiovascular diseases and type 2 diabetes mellitus","volume":"39","author":"Katsiki","year":"2018","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.urology.2025.04.056_bib42","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.urology.2025.04.056_bib43","doi-asserted-by":"crossref","first-page":"e793","DOI":"10.1161\/CIR.0000000000000467","article-title":"Estimating longitudinal risks and benefits from cardiovascular preventive therapies among medicare patients: the million hearts longitudinal ASCVD risk assessment tool: a special report from the American Heart Association and American College of Cardiology","volume":"135","author":"Lloyd-Jones","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.urology.2025.04.056_bib44","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJMoa1209978","article-title":"Long-term functional outcomes after treatment for localized prostate cancer","volume":"368","author":"Resnick","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2025.04.056_bib45","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.urology.2025.04.056_bib46","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon-like peptide -1\u2013based therapies and mitigation strategies","volume":"26","author":"Neeland","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.urology.2025.04.056_bib47","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1249\/MSS.0000000000001074","article-title":"Effects of weight loss on lean mass, strength, bone, and aerobic capacity","volume":"49","author":"Weiss","year":"2017","journal-title":"Med Sci Sports Exerc"},{"key":"10.1016\/j.urology.2025.04.056_bib48","unstructured":"Higgason N, Fang AM, Chapin BF, et al. Post-operative complications following radical prostatectomy among men taking GLP-1 agonists. [Poster presentation]. South Central Section of the AUA 2024. Colorado Springs, CO."},{"key":"10.1016\/j.urology.2025.04.056_bib49","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13543","article-title":"Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: a network meta-analysis of randomized clinical trials","volume":"24","author":"Alkhezi","year":"2023","journal-title":"Obes Rev Off J Int Assoc Study Obes"},{"key":"10.1016\/j.urology.2025.04.056_bib50","doi-asserted-by":"crossref","first-page":"150.e9","DOI":"10.1016\/j.urolonc.2016.11.010","article-title":"Evaluating the effect of time from prostate cancer diagnosis to radical prostatectomy on cancer control: Can surgery be postponed safely?","volume":"35","author":"Fossati","year":"2017","journal-title":"Urol Oncol"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429525004261?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429525004261?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T04:07:38Z","timestamp":1750478858000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429525004261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":50,"alternative-id":["S0090429525004261"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2025.04.056","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1 Agonist Use Among Men With Localized Prostate Cancer: A Narrative Review and Rationale for Prospective Clinical Trials","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2025.04.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}